CBD and Schizophrenia

Peer-reviewed studies into the potential effects of Cannabidiol and Schizophrenia

On this page, CBD and Schizophrenia, you will find research pertaining to the use of Cannabidiol and Cannabinoids and its possible effects on Schizophrenia. The information below is not meant to influence your opinion, but rather give you access to a wealth of scientific literature in an attempt to make and educated and informed choice. Click Here to see all of the conditions that have been researched alongside CBD and Schizophrenia.

 

Reuters: Cannabis drug shows promis in treating schizophrenia

From the article:

An experimental cannabis drug for treating schizophrenia, developed by UK-based GW Pharmaceuticals Plc, was found to be superior to a placebo in a mid-stage trial… The drug, cannabidiol, was tested in 88 patients with schizophrenia, who had failed to respond to anti-psychotic medication…  

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

From the abstract:

The antipsychotic-like properties of CBD have been investigated in animal models using behavioral and neurochemical techniques which suggested that CBD has a pharmacological profile similar to that of atypical antipsychotic drugs. The results of two studies on healthy volunteers using perception of binocular depth inversion and ketamine-induced psychotic symptoms supported the proposal of the antipsychotic-like properties of CBD. In addition, open case reports of schizophrenic patients treated with CBD and a preliminary report of a controlled clinical trial comparing CBD with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia.

Cannabidiol as a potential treatment for psychosis.  

From the abstract:

Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties... Evidence from several research domains suggests that CBD shows potential for antipsychotic treatment.

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

From the abstract:

Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms..results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.

Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

From the abstract:

The medical properties of cannabis have been known for many centuries; its first documented use dates back to 2800 BC when it was described for its hallucinogenic and pain-relieving properties... Recently, great attention has been directed to the medical properties of phytocannabinoids present in the cannabis plant alongside the main constituent Δ⁹-Tetrahydrocannabinol (THC); these include cannabinoids such as cannabidiol (CBD)… Evidence suggests that CBD can ameliorate positive and negative symptoms of schizophrenia. Behavioural and neurochemical models suggest that CBD has a pharmacological profile similar to that of atypical anti-psychotic drugs and a clinical trial reported that this cannabinoid is a well-tolerated alternative treatment for schizophrenia.

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

From the abstract:

Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal models and in healthy volunteers. Thus, this article provides a critical review of the research evaluating antipsychotic potential of this cannabinoid. CBD appears to have pharmacological profile similar to that of atypical antipsychotic drugs as seem using behavioral and neurochemical techniques in animal models. Additionally, CBD prevented human experimental psychosis and was effective in open case reports and clinical trials in patients with schizophrenia with a remarkable safety profile.

Peripheral endocannabinoid system dysregulation in first-episode psychosis.

From the abstract:

The alteration of the ECS presented at the initial phases of psychosis could be contributing to the pathophysiology of the disease and constitutes a possible biomarker of psychotic disorders and an interesting pharmacological target to take into account for therapeutic purposes.

Cannabinoids and schizophrenia: therapeutic prospects. 

From the abstract:

Approximately one third of patients diagnosed with schizophrenia do not achieve adequate symptom control with standard antipsychotic drugs (APs)..The anti-inflammatory and immunomodulatory effects of the non-intoxicating phytocannabinoid cannabidiol (CBD) are well established and are summarised below. Preliminary data reviewed in this paper suggest that CBD in combination with a CB1 receptor neutral antagonist could not only augment the effects of standard APs but also target the metabolic, inflammatory and stress-related components of the schizophrenia phenotype.

Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies.

From the abstract:

Several lines of experimental and clinical evidence point to a close relationship between cannabis, the endogenous cannabinoid system, and schizophrenia. A variety of animal and human studies found a dysregulation of endocannabinoid signalling in psychosis..results predominantly confirm the hypothesis of an antipsychotic activity of both cannabinoids. In comparison, cannabidiol appears to be superior to rimonabant with a pharmacological profile similar to atypical antipsychotic drugs.

Cannabis with high cannabidiol content is associated with fewer psychotic experiences.

From the abstract:

Although the observed effects are subtle, using high cannabidiol content cannabis was associated with significantly lower degrees of psychotic symptoms providing further support for the antipsychotic potential of cannabidiol

Marijuana Compound Treats Schizophrenia with Few Side Effects: Clinical Trial

From the article:

Nineteen patients were treated with amisulpride, an antipsychotic medication that is not approved in the U.S., but is comparable to other medications that are. The rest of the patients were given cannabidiol (CBD), a substance found in marijuana that is thought to be responsible for some of its mellowing or anxiety-reducing effects..both groups showed significant clinical improvement in their schizophrenic symptoms, and there was no difference between those getting CBD or amisulpride.

Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments.

From the abstract:

Growing clinical and pre-clinical evidence points to a critical role for cannabidiol (CBD), the largest phytochemical component of cannabis, as a potential pharmacotherapy for various neuropsychiatric disorders..Together with clinical evidence showing that CBD may normalize affective and cognitive deficits associated with schizophrenia, CBD may represent a promising treatment for 

Improved Social Interation, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (Poly I:C) Rat Model.

From the abstract:

In conclusion, chronic CBD administration can attenuate the social interaction and cognitive deficits induced by prenatal poly I:C infection [induced schizophrenic effects]. These novel findings present interesting implications for potential use of CBD in treating the cognitive deficits and social withdrawal of schizophrenia.